# Damora Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Damora Therapeutics, Inc.). ## Overview Damora Therapeutics, Inc. is a clinical-stage biotechnology company developing novel small-molecule therapeutics for cancer and liver diseases. The company is focused on product candidates GB1211 and GB3226, targeting areas with high unmet medical need and no disease-modifying treatment options. ## Products & services • GB3226 preclinical oncology and liver disease program • GB1211 clinical-stage small-molecule therapeutic program • Discovery and preclinical development of new product candidates • Clinical development, regulatory filing and IND-enabling work • Potential future commercialization of approved therapies - **GB3226** (50%) — Preclinical small-molecule program being advanced toward IND submission and later clinical development. - **GB1211** (35%) — Clinical-stage product candidate in the company's oncology and liver disease pipeline. - **Discovery and pipeline expansion** (10%) — Research, in-licensing and development of additional product candidates and technologies. - **Future commercialization** (5%) — Potential sales, marketing, medical affairs and distribution activities if candidates are approved. - GB3226 preclinical oncology and liver disease program - GB1211 clinical-stage small-molecule therapeutic program - Discovery and preclinical development of new product candidates - Clinical development, regulatory filing and IND-enabling work - Potential future commercialization of approved therapies ## Customers Damora does not currently sell approved products; its near-term 'customers' are regulators, clinical trial participants, and contract research/manufacturing partners that enable development. If its programs succeed, the end-market customers would be patients with cancer or liver disease, along with physicians, hospitals and third-party payors that influence adoption and reimbursement. - **Regulatory authorities** (primary) — FDA, EMA and other agencies review preclinical and clinical data and determine whether programs can advance. - **CRO and CMO partners** (primary) — Contract research and manufacturing organizations provide trial execution, testing and drug supply. - **Patients with oncology and liver disease** (secondary) — Future end users of approved therapies if GB1211, GB3226 or other candidates reach market. - **Physicians and hospitals** (secondary) — Clinical decision-makers who would adopt the therapies based on efficacy, safety and convenience. - **Third-party payors** (secondary) — Commercial and government payors that would determine access through coverage and reimbursement. - Regulators such as the FDA and EMA for trial and IND approvals - CROs and CMOs that run studies and manufacture drug supply - Patients with cancer or liver disease in future clinical use - Physicians and medical centers that would prescribe approved therapies - Third-party payors that determine coverage, pricing and reimbursement ## Geography Damora is headquartered in the United States and its development work is centered on U.S. regulatory pathways, especially FDA interactions for GB3226. The company also references EMA and other foreign regulators, and it relies on international supply chains and third-party manufacturers, which creates exposure to trade policy and cross-border operating risk. - United States is the core operating and regulatory base - FDA is central to GB3226 IND and clinical development plans - EMA and other foreign regulators may matter for future expansion - International CRO/CMO supply chains create cross-border execution risk - Trade policy and tariffs can raise input and manufacturing costs ## Strategy The company is prioritizing GB3226 and GB1211, with GB3226 expected to advance through preclinical work and toward an IND filing. It is also seeking additional capital and potential collaborations to fund clinical development, while building the operational, regulatory and manufacturing capabilities needed for eventual commercialization. - **Advance GB3226 to IND submission** (short-term) — This is the clearest near-term value-creation milestone and supports progression into clinical development. - **Fund the pipeline through additional capital** (short-term) — The company expects substantial additional funding needs and has going-concern risk without financing. - **Build development and commercialization infrastructure** (medium-term) — Clinical-stage biotech requires regulatory, manufacturing and commercial capabilities before launch. - **Protect intellectual property and secure partnerships** (medium-term) — Pipeline value depends on patent protection, exclusivity and access to external expertise and capital. - Advance GB3226 through preclinical work and IND submission - Continue development of GB1211 and other pipeline assets - Raise equity, convertible debt or collaboration funding - Build clinical, quality and management infrastructure - Secure manufacturing and future commercialization capabilities ## Risks Damora is a pre-revenue biotech with substantial going-concern and financing risk because it must fund long development cycles before any product revenue can emerge. Its business also depends on clinical success, regulatory approvals, IP protection and outsourced manufacturing, while trade restrictions and supply-chain disruptions can increase costs and delay programs. - **Insufficient financing and going-concern risk** [critical] — The company states it will require substantial additional capital and may need to cut or stop programs if funding is unavailable. - **Clinical development and regulatory failure** [high] — Product candidates must succeed in preclinical and clinical studies and obtain FDA/other approvals before commercialization. - **Outsourced manufacturing and supply-chain disruption** [high] — The company relies on third-party manufacturers and international inputs for preclinical and clinical supply. - **Intellectual property and competition risk** [high] — Value depends on maintaining patents, exclusivity and freedom to operate against competing therapies and third-party IP claims. - **Trade policy and geopolitical risk** [medium] — Tariffs, import restrictions and geopolitical instability can raise costs and delay research or manufacturing activities. - Going-concern risk if additional capital is not raised - Clinical failure or delays could eliminate program value - Regulatory approval risk for INDs and future marketing applications - Dependence on CROs, CMOs and third-party supply chains - IP disputes or loss of exclusivity could weaken competitive position ## Accounting The most important accounting issue is estimating research and development accruals for CROs, CMOs and other vendors, because trial timing and invoices often lag the underlying work. Investors should also watch going-concern disclosures, stock-based compensation and deferred tax valuation allowances, since the company is loss-making and has limited near-term revenue visibility. - **Research and development accruals** — Can materially shift quarterly operating loss and working capital - **Going-concern assessment** — Important for liquidity analysis and capital structure risk - **Deferred tax assets and valuation allowance** — Can affect tax benefit recognition and equity - **Clinical trial cost timing** — Reduces comparability of period-to-period R&D spend - R&D accrual estimates affect reported expense and liabilities - Clinical trial timing can cause quarter-to-quarter expense swings - Going-concern assessment reflects financing uncertainty - Deferred tax assets may require valuation allowances - Public-company and equity compensation costs add overhead --- *Last updated: 2026-04-28T20:01:24.362790+00:00*